

# Syros Pharmaceuticals to Participate in Two Upcoming Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals announced today that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at the upcoming BioCentury 23<sup>rd</sup> Annual Future Leaders in the Biotechnology Industry Conference. The Company's management team will also participate in next week's Cowen and Company 36<sup>th</sup> Annual Health Care Conference. Additional details are as follows:

# Cowen and Company 36<sup>th</sup> Annual Health Care Conference

Date: Monday, March 7 to Wednesday, March 9

Location: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, Mass.

## **BioCentury 23rd Annual Future Leaders in the Biotech Industry Conference**

Date: Friday, March 11 Time: 2:00 pm ET Room: Room 311

Location: Millennium Hotel, 145 West 44th Street, New York, NY

### **About Syros Pharmaceuticals**

Syros Pharmaceuticals is a biopharmaceutical company applying a pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other serious diseases. Syros has built a proprietary gene control platform that provides the Company with a unique lens to identify crucial genes that become dysregulated in diseased cells. Syros is leveraging its platform to develop a pipeline of gene control product candidates that it believes will provide a profound and durable benefit for patients. The Company's scientific founders are world-class leaders in gene control research and translation. Launched by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Cambridge, Mass.

View source version on businesswire.com: <a href="http://www.businesswire.com/news/home/20160303005455/en/">http://www.businesswire.com/news/home/20160303005455/en/</a>

#### Media Contact:

Ten Bridge Communications, Inc.
Naomi Aoki, 617-283-4298
<a href="mailto:naomi@tenbridgecommunications.com">naomi@tenbridgecommunications.com</a>
or

#### Investor Contact:

Stern Investor Relations, Inc. Jesse Baumgartner, 212-362-1200 jesse@sternir.com

Source: Syros Pharmaceuticals